These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31011452)

  • 21. Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy.
    Lin M; Mao Y; Ai S; Liu G; Zhang J; Yan J; Yang H; Li A; Zou Y; Liang D
    Int J Endocrinol; 2015; 2015():285698. PubMed ID: 26221138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
    Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
    Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of selenium supplementation versus placebo in the treatment of Graves' orbitopathy: A systematic review and meta-analysis of randomised controlled trials.
    Sharabati I; Qafesha RM; Hindawi MD; Amro S; Ayesh BM
    Clin Endocrinol (Oxf); 2024 Dec; 101(6):669-681. PubMed ID: 39138905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.
    Perros P; Hegedüs L; Bartalena L; Marcocci C; Kahaly GJ; Baldeschi L; Salvi M; Lazarus JH; Eckstein A; Pitz S; Boboridis K; Anagnostis P; Ayvaz G; Boschi A; Brix TH; Currò N; Konuk O; Marinò M; Mitchell AL; Stankovic B; Törüner FB; von Arx G; Zarković M; Wiersinga WM
    Orphanet J Rare Dis; 2017 Apr; 12(1):72. PubMed ID: 28427469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions.
    Campi I; Currò N; Vannucchi G; Covelli D; Simonetta S; Fugazzola L; Dazzi D; Pignataro L; Guastella C; Lazzaroni E; Pirola G; Salvi M
    Thyroid; 2021 Feb; 31(2):280-287. PubMed ID: 32940167
    [No Abstract]   [Full Text] [Related]  

  • 27. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The influence factors of quality-of-life in patients with thyroid-associated ophthalmopathy].
    Shen L; Zhu H; Li XX; Liu DD; Chen XY; Liu H
    Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):575-582. PubMed ID: 28851197
    [No Abstract]   [Full Text] [Related]  

  • 29. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial.
    Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S;
    Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
    Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
    Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Objective and subjective outcomes of strabismus surgery in Graves' orbitopathy: a prospective multicentre study.
    Jellema HM; Saeed P; Mombaerts I; Dolman PJ; Garrity J; Kazim M; Dhrami-Gavazi E; Lyons C; Nieuwkerk P; Mourits MP
    Acta Ophthalmol; 2017 Jun; 95(4):386-391. PubMed ID: 28133945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and psychometric properties of the Thai Graves' ophthalmopathy quality of life (GO-QOL) questionnaire.
    Lumyongsatien M; Keeratidamkerngsakul B; Pornpanich K; Vangveeravong S; Saonanon P; Wiwatwongwana D; Mahaisavariya P; Aryasit O; Pongpirul K
    J Patient Rep Outcomes; 2019 Dec; 4(1):1. PubMed ID: 31893319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments.
    Terwee CB; Dekker FW; Mourits MP; Gerding MN; Baldeschi L; Kalmann R; Prummel MF; Wiersinga WM
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):391-8. PubMed ID: 11298093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life in Graves' ophthalmopathy.
    Wiersinga WM
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):359-70. PubMed ID: 22632371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study.
    Wang C; Qiao J; Liu S; Piao S; Zhou Y; Hu Y; Wan C; Sun Y; Ning H; Chen L; Zhang H; Hu R; Wang H; Wang W; Zhao L; Mao J; Li M; Teng W; Shan Z; Li Y
    Endocrine; 2024 Jun; 84(3):1072-1080. PubMed ID: 38200401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome of Graves' orbitopathy following treatment with sirolimus.
    Comi S; Cosentino G; Lanzolla G; Menconi F; Maglionico MN; Posarelli C; Latrofa F; Rocchi R; Figus M; Santini F; Marinò M
    J Endocrinol Invest; 2024 Oct; ():. PubMed ID: 39373962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of quality of life in patients with Graves´ ophthalmopathy, before and after orbital decompression.
    Iacobæus L; Sahlin S
    Orbit; 2016 Jun; 35(3):121-5. PubMed ID: 27159575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
    Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
    J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
    Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.